camicinal
Small moleculeexperimental
Camicinal was a motilin agonist investigated for the treatment of gastroparesis. It did not improve enteral feeding intolerance. — Wikipedia
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00562848)
Timeline
Indications
Studied for
Mechanism of action
- Motilin receptorAGONIST
MLNR agonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1CN(Cc2ccc(CC(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)CCN1- Mol. weight
- 424.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCamicinal ↗
- ChEMBLCHEMBL489095 ↗
Also known as
- camicinal
- camicinal
- camicinal
- camicinal
- comicinal
- gsk962040
- gsk962040
- gsk962040
- gsk962040
- gsk962040b
- gsk962040b
- n-(3-fluorophenyl)-1-((4-(((3s)-3-methyl-1-piperazinyl)methyl)phenyl)acetyl)-4-piperidinamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02210000 | Phase 2 | Aug 1, 2014 | GlaxoSmithKline |
| NCT01934192 | Phase 2 | Apr 1, 2014 | GlaxoSmithKline |
| NCT01602549 | Phase 2 | Jul 1, 2012 | GlaxoSmithKline |
| NCT01262898 | Phase 2 | May 1, 2011 | GlaxoSmithKline |
| NCT01039805 | Phase 2 | Dec 1, 2009 | GlaxoSmithKline |
| NCT01039974 | Phase 1 | Sep 18, 2009 | GlaxoSmithKline |
| NCT00861809 | Phase 2 | Jun 1, 2009 | GlaxoSmithKline |
| NCT00733551 | Phase 1 | Sep 1, 2008 | GlaxoSmithKline |
| NCT00562848 | Phase 1 | Sep 1, 2007 | GlaxoSmithKline |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 9 | 9 | 2 | 2007 |
1 organizations
Page 1 / 1